KEY MESSAGES This systematic review and meta-analysis of randomized clinical trials (RCTs) evaluated the clinical efficacy and safety of interleukin-1 (IL-1) blockade for patients with COVID-19. Based on the analysis of six RCTs, no significant difference in the all-cause mortality rate of patients with COVID-19 was observed between the IL-1 blockade and control groups. The study group using IL1 was associated with a significantly lower risk of requiring mechanical ventilation compared with the control group. The risk of adverse events was similar between the study and the control groups.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Anakinra, interleukin-1, canakinumab,
【저자키워드】 COVID-19, SARS-CoV-2, Anakinra, interleukin-1, canakinumab,